An investment bank has moderated its generally bullish view on Q3 earnings expectations for a Wall Street sweetheart.
After July rumblings of increased fees and lack of reimbursements for this medtech company’s products, a recent survey shows uptake is growing above expectations.
Legislation changes and a tie up with another major medtech innovator help propel this company’s product into every operating room.
The global semiconductor shortage calls for capital investments. Commodity inflation is here. CPIs are low still, but long bonds sell off. Biotech is a sweet spot.
We update some notes on 20 stocks that we have covered on our blog and Telegram channel. Many present very compelling opportunities right now.
A high flying medical diagnostics company has investors scared of falling revenue after COVID vaccines become available. The reaction was a strong sell off and now the stock is back on track towards its all time highs.
U.S., estimated annual dialysis spending approximates $74B and the main market players have not changed for 30 years. A new medtech company is set to disrupt the market.
We are following up on a recent IPO idea published on our telegram channel. This Medtech company looks towards a post COVID expansion in Europe and Asia.
We highlighted in various webinars and last weeks FIT that MedTech is a strong sector currently. We review a trade idea in that sector.
Two companies compete in a large and growing diabetes market in the US. New technology brings a complementary, yet competitive product to the market that is gaining market share. Is a take over opportunity coming?